Eprosartan mesylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for eprosartan mesylate and what is the scope of freedom to operate?
Eprosartan mesylate
is the generic ingredient in three branded drugs marketed by Norvium Bioscience and Abbvie, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for eprosartan mesylate.
Summary for eprosartan mesylate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 2 |
| NDAs: | 3 |
| Drug Master File Entries: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 77 |
| Clinical Trials: | 1 |
| Patent Applications: | 2,167 |
| DailyMed Link: | eprosartan mesylate at DailyMed |
Recent Clinical Trials for eprosartan mesylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Quintiles, Inc. | Phase 3 |
| Abbott | Phase 3 |
| author! et al. BV | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for eprosartan mesylate
Paragraph IV (Patent) Challenges for EPROSARTAN MESYLATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TEVETEN | Tablets | eprosartan mesylate | 400 mg and 600 mg | 020738 | 1 | 2010-05-10 |
US Patents and Regulatory Information for eprosartan mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norvium Bioscience | EPROSARTAN MESYLATE | eprosartan mesylate | TABLET;ORAL | 202012-002 | Nov 16, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-004 | Dec 22, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-005 | Dec 22, 1997 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for eprosartan mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-004 | Dec 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-005 | Dec 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-006 | May 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Abbvie | TEVETEN | eprosartan mesylate | TABLET;ORAL | 020738-006 | May 27, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
